PMID: 11336385May 5, 2001Paper

Synthetic hydrogels as carriers in antisense therapy: preliminary evaluation of an oligodeoxynucleotide covalent conjugate with a copolymer of 1-vinyl-2-pyrrolidinone and 2-hydroxyethyl methacrylate

Journal of Biomaterials Applications
X LouT V Chirila

Abstract

A major challenge of the antisense therapeutic strategies is the development of improved systems for the delivery of antisense oligodeoxynucleotides (AS ODNs) in order to enhance the cellular uptake, to assure a better efficiency in reaching the target tissue, and to provide sustained delivery over longer periods of time. Because the current methods for delivery (liposomes and cationic polymers) present some disadvantages, the attention was directed toward the use of neutral polymers as carriers for the AS ODNs. Based on our previous work on synthetic hydrogels for vitreous substitution, we developed a poly[1-vinyl-2-pyrrolidinone-co-(2-hydroxyethyl methacrylate)] hydrogel as a potential carrier for AS ODNs. We have previously demonstrated that such hydrogels are not cytotoxic, and they may have growth-promoting effects on cultured fibroblasts. This copolymer also has the advantage of being injectable. In this study, a specific AS ODN was synthesized and then covalently bound to the copolymer via carbodiimide coupling method. The resulting conjugate was subjected to in vitro release experiments over 46 days in the presence of bovine vitreous humor. Compared with the control (no enzyme present), a significant amount of covalentl...Continue Reading

References

Jan 1, 1992·Antisense Research and Development·R L Juliano, S Akhtar
Jan 1, 1992·Methods in Enzymology·E Taillandier, J Liquier
Jan 1, 1992·Annual Review of Pharmacology and Toxicology·S T Crooke
Jun 16, 1989·Science·T Friedmann
Jun 16, 1989·Science·M R Capecchi
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S L LokeL M Neckers
May 1, 1970·Vision Research·L MitraniN Yakimoff
Feb 1, 1995·Circulation Research·E R EdelmanR D Rosenberg
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SchwabE Saison-Behmoaras
Jan 1, 1994·Pharmaceutica acta Helvetiae·H Schreier
Jan 1, 1993·Antisense Research and Development·R M Bennett
Jan 1, 1993·Progress in Nucleic Acid Research and Molecular Biology·J P LeonettiB Lebleu
Nov 1, 1995·Bioconjugate Chemistry·A V Kabanov Alakhov VYu
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·A M GewirtzP M Glazer
Jan 1, 1996·Journal of Biomaterials Science. Polymer Edition·S VijayasekaranI L McAllister
Jan 1, 1995·Antisense Research and Development·Q ZhaoS Agrawal
Jul 1, 1996·Medicinal Research Reviews·S T Crooke
Apr 1, 1996·Journal of Biomedical Materials Research·Y HongI J Constable
Mar 1, 1996·Leukemia & Lymphoma·A TariG Lopez-Berestein
Nov 1, 1996·American Journal of Respiratory and Critical Care Medicine·S AsakuraA H Limper
Oct 1, 1996·Journal of Biomaterials Applications·Y HongI J Constable
Jun 1, 1997·Scientific American·T Friedmann
Jan 1, 1997·Journal of Drug Targeting·R I MahatoM Hashida
May 14, 1998·Gene Therapy·R J Yáñez, A C Porter
Feb 16, 2000·Progress in Retinal and Eye Research·A BochotE Fattal
Jun 6, 2000·Advanced Drug Delivery Reviews·E S Ron, L E Bromberg

❮ Previous
Next ❯

Citations

Aug 7, 2002·Antisense & Nucleic Acid Drug Development·Wolfgang Nedbal, Birgit Teichmann
Jul 11, 2008·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Luciana DiniPiera Angela Ramires
Jun 17, 2015·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·S Mariacher, P Szurman
Sep 1, 2001·The Journal of Gene Medicine·K L GarrettP E Rakoczy
Sep 14, 2006·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Francisco García-EsteoJuan Manuel Bellón

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.